Long-term QUILT-3.032 findings show durable responses with Anktiva plus BCG in BCG-unresponsive NMIBC, with an estimated 84.2% cystectomy-free survival at 3 years. Nogapendekin alfa inbakicept ...

National use of focal therapy was uncommon overall but frequently extended beyond guideline-supported settings, highlighting potential misalignment between practice patterns and AUA/ASTRO ...

The following FAQs highlight key recommendations and practical takeaways from the 2026 AUA/SUO Advanced Prostate Cancer Guideline. Two overarching themes define the 2026 amendment: the consolidation ...

Labeling would drop the limitation of use for age-related hypogonadism, reflecting an evidence reassessment that no longer supports language implying unestablished safety and effectiveness in this ...

A comprehensive guide to the practice-changing, paradigm-shifting studies across urologic oncology. Urologists will soon gather in Washington, DC, for the 2026 Annual Meeting of the American ...

De novo authorization establishes a new FDA classification category for reusable intermittent catheter systems, enabling a regulatory pathway distinct from traditional single-use intermittent ...

FDA 510(k) clearance enables use of external neuromuscular stimulation to strengthen pelvic floor musculature and improve bladder control in men with post-prostatectomy incontinence. Daily home ...

The system can be used as an irrigation option for ureteroscopy, cystoscopy, percutaneous nephrolithotomy, and benign prostatic hyperplasia procedures. The FDA has granted 510(k) clearance to the ...

Boxed warnings were removed from Prometrium, Divigel, Cenestin, Enjuvia, Estring, and Bijuva, spanning progestogen-only, systemic estrogen-only, topical vaginal estrogen, and combined systemic ...

AVA-291 is a novel testosterone formulation for women, designed to resist aromatization and reduce breast cancer risk. Data shows AVA-291 has a 1,000-fold lower potential to stimulate breast cancer ...

"The overall 0% impact to urology does not help urology practices deal with increasing costs incurred for staff, rent, supplies, and other overhead," write Jonathan Rubenstein, MD, and Mark Painter.

Pasritamig targets KLK2 and has FDA fast track designation for mCRPC, enabling accelerated development and review processes. Phase 1 study showed pasritamig was well-tolerated with promising antitumor ...